Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Purespring Therapeutics

Request full access

AAV gene therapy platform targeting chronic kidney diseases

London, United KingdomFounded 2020Biotech & Life Sciences

About Purespring Therapeutics

Purespring Therapeutics is a London-based biotechnology company established in 2020 by Syncona, a life science investor, and built upon the research of founders Professor Moin Saleem and Mauro Giacca. The company is a pioneer in developing adeno-associated virus (AAV) gene therapies specifically for chronic kidney diseases, an area with significant unmet medical needs. Purespring's scientific foundation is the work of Professor Moin Saleem of the University of Bristol, a leader in pediatric renal medicine whose research has focused on the podocyte—a specialized kidney cell critical to filtration and implicated in approximately 60% of renal diseases.

The company's proprietary platform is engineered to deliver gene therapies directly to podocytes, offering the potential to halt or even reverse kidney disease by correcting defective genes or modulating protein production. This targeted approach aims to provide curative treatments for both rare monogenic and more common kidney conditions, moving beyond options like dialysis or transplantation which only manage late-stage disease. Purespring's business model is centered on the research, development, and eventual commercialization of these novel therapies. Revenue generation is anticipated through product sales and strategic partnerships within the pharmaceutical and healthcare sectors.

Purespring has secured significant funding to advance its pipeline, raising approximately $60 million in a Series A round in 2020 and $105 million in a Series B round in October 2024. This capital is being used to progress its lead candidate, PS-002 for IgA Nephropathy (IgAN), into a Phase I/II clinical trial. The company's pipeline also includes programs for other conditions, such as steroid-resistant nephrotic syndrome. Preclinical data has demonstrated the platform's ability to successfully deliver genetic material to podocytes in animal models, restoring kidney function and showing no off-target effects or safety concerns.

Source: Dealroom company data

At a glance

Status
Operational
Employees
56
Open positions
None listed
Dealroom signal
73.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Spinout, Disease, DT and LS, uk is8 life sciences, UKSU, UKSU2010, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Oct 2024 $106M $422M British Patient Capital · Syncona · Sofinnova Partners · Forbion Capital Partners ↗
SERIES AOther financing Nov 2020 $59M $238M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Purespring Therapeutics website traffic

Latest recorded traffic for Purespring Therapeutics is 3.6K monthly website visits, up 227.3% over the last three months. Purespring Therapeutics's team grew 1.8% over the past year.

Latest monthly visits3.6K 3-month web change+227.3% 1-year team growth+1.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Purespring Therapeutics in the London ecosystem

Live from Dealroom

The Purespring Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Sofinnova Partners
  • British Patient Capital
  • Syncona
  • Forbion Capital Partners
  • Gilde Healthcare

Other known investors1 additional known investor

  • University of Bristol
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇬🇧 United Kingdom95.8%
🇳🇱 Netherlands2.1%
🇨🇭 Switzerland2.1%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Purespring Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Purespring Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.